THE DEPENDENCE OF THE EXPRESSION OF CCR7 BY MONOCYTE-DERIVED DENDRITIC CELLS ON THE MATURATION COMPOUND
S.V. Sazonov¹,², F.A. Fadeyev¹,², A.D. Nikanorova², A.V. Zamyatin³
DOI: 10.22138/2500-0918-2022-19-1-14-22
¹ Ural State Medical University, Yekaterinburg, Russian Federation;
² Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation;
³ Sverdlovsk Regional Oncological Dispensary, Yekaterinburg, Russian Federation
Abstract. Dendritic cells (DCs), loaded with tumor antigens, are widely investigated as a potential therapeutic tool for cancer treatment. CCR7 plays the key role in DCs migration to lymph nodes for the anti-tumor immune response activation.
The purpose of this study was to investigate the effect of different compositions for DC maturation on the CCR7 expression.
Materials and methods. DCs were derived from peripheral blood monocytes in medium supplemented with GM-CSF and IL-4. Five different compounds were used for stimulation of DCs maturation. The expression of CCR7 was evaluated by flow cytometry.
Results and discussion. The highest level of CCR7 expression was seen when the ‘‘cytokine cocktail” (TNF+IL-1+IL-6+PGE2) or the poly I:C were used for the stimulation of cell maturation. At the same time, the immunosuppressive effect of PGE2 and poly I:C cannot be excluded. Therefore, additional investigations of functionality of DCs after induced maturation are required.
Keywords: dendritic cells, CCR7 expression, stimulation of maturation
There is no conflict of interest.
Contact details of the corresponding author:
Fedor A. Fadeyev
fdf79@mail.ru
Received 13.02.2021
For citation:
Sazonov S.V., Fadeyev F.A., Nikanorova A.D., Zamyatin A.V. The dependence of the expression of CCR7 by monocyte-derived dendritic cells on the maturation compound. [Online] Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2022, Vol. 19, no. 1, pp. 14–22. DOI: 10.22138/2500-0918-2022-19-1-14-22 (In Russ)
REFERENCES
1. Burgdorf, S.K., Fischer, A., Myschetzky, P.S., Munksgaard, S.B., Zocca, M., Claesson, M.H., & Rosenberg, J. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncology Reports. 2008. Vol. 20. pp. 1305-1311. DOI:10.3892/or_00000145
2. Elishev V.G., Mikerov I.A., Fadeev F.A., Leontiev S.L., Brilliant A.A., Shirokova O.N., Zubareva N.A., Kovaleva I B., Emelyanov D.E., Zamyatin A.V. The results of antitumor dendritic cell vaccines use in patients with metastatic forms of malignant neoplasms and exhausted possibilities of standard therapy. Ural Medical Journal. 2020. Vol. 2 (185). pp. 31-33. DOI 10.25694/URMJ.2020.02.08
3. van Gulijk M., Dammeijer F., Aerts J.G.J.V., Vroman H. Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy. Front. Immunol. 2018. Vol. 9. 2759. DOI:10.3389/fimmu.2018.02759.
4. Nestle, F.O., Farkas, A., Conrad, C. Dendritic-cell-based therapeuticvaccination against cancer. Curr. Opin. Immunol. 2005. Vol. 17. pp. 163–169. DOI:10.1016/j.coi.2005.02.003.
5. Weber, M., Hauschild, R., Schwarz, J., Moussion, C., de Vries, I., Legler, D.F., et al. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science. 2013. Vol. 339. pp. 328–332. DOI:10.1126/science.1228456
6. Tal, O., Lim, H.Y., Gurevich, I., Milo, I., Shipony, Z., Ng, L.G., et al. DC mobilization from the skin requires docking to immobilized CCL21 onlymphatic endothelium and intralymphatic crawling. J. Exp. Med. 2011. Vol. 208. pp. 2141–2153. DOI: 10.1084/jem.20102392.
7. Nehaeva, T.L. Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Neoplasms. Siberian journal of oncology. 2013;(3): 52-56. (In Russ.)
8. Fadeyev F.A., Zamyatin A.V., Sedneva-Lugovets D.V., Mikerov I.A., Gubaeva O.V. Generation of dendritic cells for cancer therapy. Journal of Ural Medical Academic Science. 2020. Vol. 7, No. 4. pp. 347-353.
9. Chabot, V., Martin, L., Meley, D., Sensebé, L., Baron, C., Lebranchu, Y., Dehaut, F., Velge-Roussel, F. Unexpected impairment of TNF-α-induced maturation of human dendritic cells in vitro by IL-4. Journal of translational medicine. 2016. Vol. 14:93. DOI: 10.1186/s12967-016-0848-2
10. Muthuswamy, R., Mueller-Berghaus, J., Haberkorn, U., Reinhart, T. A., Schadendorf, D., & Kalinski, P. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells // Blood. 2010. V. 116(9). P. 1454–1459. DOI: 10.1182/blood-2009-12-258038
11. Matsumoto, M., Takeda, Y., Tatematsu, M., & Seya, T. Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. Frontiers in immunology. Vol. 2017. Vol. 8: 1897. DOI: 10.3389/fimmu.2017.01897
12. Castiello, L., Sabatino, M., Jin, P., Clayberger, C., Marincola, F. M., Krensky, A. M., & Stroncek, D. F. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer immunology, immunotherapy. 2011. Vol. 60(4). pp. 457–466. DOI: 10.1007/s00262-010-0954-6
13. Nakahara, T., Uchi, H., Urabe, K., Chen, Q., Furue, M., & Moroi, Y. Role of c-Jun N-terminal kinase on lipopolysaccharide induced maturation of human monocyte-derived dendritic cells. International immunology. 2004. Vol. 16 (12). pp. 1701–1709. DOI:10.1093/intimm/dxh171
14. Trabanelli, S., Lecciso, M., Salvestrini, V., Cavo, M., Očadlíková, D., Lemoli, R. M., & Curti, A. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. Journal of immunology research. Vol. 2015: 253191. DOI:10.1155/2015/253191
15. Krause, P., Singer, E., Darley, P. I., Klebensberger, J., Groettrup, M., & Legler, D. F. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. Journal of leukocyte biology. 2007. Vol. 82 (5). pp. 1106–1114. DOI:10.1189/jlb.0905519
16. Pavlović, B., Tomić, S., Đokić, J., Vasilijić, S., Vučević, D., Lukić, J., Gruden-Movsesijan, A., Ilić, N., Marković, M., & Čolić, M. Fast dendritic cells matured with Poly (I:C) may acquire tolerogenic properties. Cytotherapy. 2015. Vol. 17 (12). pp. 1763–1776. DOI: 10.1016/j.jcyt.2015.08.001
Authors
Sergey V. Sazonov
Ural State Medical University, Department of Histology, Cytology and Embryology
Institute of Medical Cell Technologies, Deputy Chief Physician for Science
MD, professor, chief of the department
Russian Federation, 620028, Yekaterinburg, Repin str., 3
prof-ssazonov@yandex.ru
Fedor A. Fadeyev
Institute of Medical Cell Technologies
Candidate of biological sciences, docent.
Chief of laboratory.
Russian Federation, 620026, Ekaterinburg, 22A Karl Marx str
fdf79@mail.ru
Anastasia D. Nikanorova
Institute of Medical Cell Technologies
Technician
Russian Federation 620026, Ekaterinburg, 22A Karl Marx str.
anastasia.nikanorova@yandex.ru.
Aleksandr V. Zamyatin
Sverdlovsk Regional Oncological Dispensary
Candidate of medical sciences
Oncologist, Chief of the personalized therapy department.
Russian Federation 620036, Ekaterinburg, 29 Sobolev str.
zamyatin.av@gmail.com
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)